EUCTR2009-012460-14-GB进行中（未招募）1 期
A phase II, open-label, randomised study to assess the safety and immunogenicity of a birth dose of GSK Biologicals’ reduced-antigen-content tri-component pertussis vaccine followed by routine paediatric vaccination at 2, 4, 6 and 12-18 months of age, and to explore the ability of this schedule to accelerate the acquisition of pertussis antibodies. - PA-TRICOMP-005
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 376
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All subjects must satisfy ALL the following criteria at study entry:
- •-Subjects who the investigator believes that their parent(s)/LAR(s) can and will
- •comply with the requirements of the protocol (e.g. completion of the diary cards,
- •return for follow-up visits).
- •-Written informed consent obtained from the parent(s)/LAR(s) of the subject.
- •-A male or female infant between, and including, 0 and 7 days of age at the time of
- •randomisation.
- •-Subjects who are born after an uncomplicated gestation period of 36 to 42 weeks
- •-Subjects born to a mother seronegative for hepatitis B surface antigen.
- •-Subjects with a birth weight >= 2.5 kg.
- •-Subjects with a 5-minute Apgar score >= 7.
- •-Healthy subjects as established by medical history and clinical examination.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The following criteria should be checked at the time of study entry. If ANY exclusion
- •criterion applies, the subject must not be included in the study:
- •-Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines since birth, or planned use during the study period.
- •-Born to a mother known or suspected to be seropositive for HIV (testing not required for inclusion).
- •-Family history of congenital or hereditary immunodeficiency.
- •-Children in care.
- •-Neonatal jaundice requiring systemic treatment (light therapy is allowed).
- •-Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
- •-Administration of any vaccine since birth or planned administration during the study period with the exception of inactivated influenza vaccines, which can be administered seven days away from any dose of the study vaccine. The administration of routinely recommended vaccines (e.g. meningococcal serogroup C conjugate vaccine, measles-mumps-rubella vaccine) is allowed during the period ffrom completion of all study-related procedures at study Visit 7 to 30 days before study Visit 8.
- •-Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- •-History of seizures or progressive neurological disease.
- •-Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •-History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
- •-Major congenital defects or serious chronic illness, including perinatal brain damage.
- •The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met:
- •-Current febrile illness or temperature >= 37.5°C on axillary setting, or >= 38.0°C on rectal setting, or other moderate to severe illness within 24 hours of study vaccine administration
研究者
相似试验
进行中（未招募）
1 期
A phase II, open-label, randomised study to assess the safety and immunogenicity of a birth dose of GSK Biologicals’ reduced-antigen-content tri-component pertussis vaccine followed by routine paediatric vaccination at 2, 4, 6 and 12-18 months of age, and to explore the ability of this schedule to accelerate the acquisition of pertussis antibodies. - PA-TRICOMP-005EUCTR2009-012460-14-NLGlaxoSmithKline Biologicals376
进行中（未招募）
1 期
A phase II, open-label, randomised study to assess the safety and immunogenicity of a birth dose of GSK Biologicals’ reduced-antigen-content tri-component pertussis vaccine followed by routine paediatric vaccination at 2, 4, 6 and 12-18 months of age, and to explore the ability of this schedule to accelerate the acquisition of pertussis antibodies. - PA-TRICOMP-005EUCTR2009-012460-14-BEGlaxoSmithKline Biologicals376
进行中（未招募）
1 期
Effects of maintenance cabozantinib+BSC versus BSC in children and AYA withosteosarcoma. ( CabOSTar )CTIS2023-506229-12-00Ipsen Innovation71
进行中（未招募）
不适用
A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancerEUCTR2004-002391-42-HUCECOG (Central European Cooperative Oncology Group)150
进行中（未招募）
不适用
A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX4 + weekly Cetuximab versus FOLFOX4 + bi-weekly Cetuximab as first-line therapy in patients with K-ras wild-type metastatic colorectal cancerEUCTR2006-006941-15-GRCECOG (Central European Cooperative Oncology Group)150